RPG Life Sciences Limited (RPGLIFE.BO)
INR 2064.1
(4.69%)
INR 2064.1
(4.69%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 5.82 Billion INR | 14.33% |
| 2022 | 5.09 Billion INR | 16.45% |
| 2021 | 4.37 Billion INR | 14.02% |
| 2020 | 3.83 Billion INR | 3.86% |
| 2019 | 3.69 Billion INR | 13.96% |
| 2018 | 3.23 Billion INR | -3.92% |
| 2017 | 3.37 Billion INR | 17.11% |
| 2016 | 2.87 Billion INR | 3.21% |
| 2015 | 2.78 Billion INR | 15.34% |
| 2014 | 2.41 Billion INR | 2.67% |
| 2013 | 2.35 Billion INR | 6.28% |
| 2012 | 2.21 Billion INR | 14.95% |
| 2011 | 1.92 Billion INR | 3.21% |
| 2010 | 1.86 Billion INR | 16.88% |
| 2009 | 1.59 Billion INR | 13.79% |
| 2008 | 1.4 Billion INR | 9.98% |
| 2007 | 1.27 Billion INR | 6.18% |
| 2006 | 1.2 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.65 Billion INR | 30.26% |
| 2023 Q1 | 1.47 Billion INR | 28.77% |
| 2023 Q2 | 1.53 Billion INR | 3.92% |
| 2023 FY | 5.82 Billion INR | 14.33% |
| 2023 Q4 | 1.26 Billion INR | -17.38% |
| 2023 Q3 | 1.53 Billion INR | 0.08% |
| 2022 Q3 | 1.3 Billion INR | -3.11% |
| 2022 Q4 | 1.14 Billion INR | -12.13% |
| 2022 FY | 5.09 Billion INR | 16.45% |
| 2022 Q2 | 1.34 Billion INR | 4.55% |
| 2022 Q1 | 1.28 Billion INR | 27.91% |
| 2021 Q3 | 1.15 Billion INR | 2.6% |
| 2021 FY | 4.37 Billion INR | 14.02% |
| 2021 Q4 | 1 Billion INR | -12.79% |
| 2021 Q1 | 1.08 Billion INR | 24.26% |
| 2021 Q2 | 1.12 Billion INR | 4.18% |
| 2020 Q1 | 916.5 Million INR | 11.43% |
| 2020 FY | 3.83 Billion INR | 3.86% |
| 2020 Q4 | 870.2 Million INR | -19.13% |
| 2020 Q3 | 1.07 Billion INR | 10.78% |
| 2020 Q2 | 971.3 Million INR | 5.98% |
| 2019 Q2 | 984.9 Million INR | 4.73% |
| 2019 FY | 3.69 Billion INR | 13.96% |
| 2019 Q1 | 940.4 Million INR | 50.32% |
| 2019 Q4 | 822.5 Million INR | -12.84% |
| 2019 Q3 | 943.7 Million INR | -4.18% |
| 2018 Q4 | 625.6 Million INR | -31.23% |
| 2018 FY | 3.23 Billion INR | -3.92% |
| 2018 Q3 | 909.7 Million INR | 0.52% |
| 2018 Q2 | 905 Million INR | 13.28% |
| 2018 Q1 | 798.9 Million INR | -4.28% |
| 2017 FY | 3.37 Billion INR | 17.11% |
| 2017 Q4 | 834.6 Million INR | -12.75% |
| 2017 Q3 | 956.6 Million INR | 6.87% |
| 2017 Q2 | 895.1 Million INR | 18.84% |
| 2017 Q1 | 753.2 Million INR | 6.05% |
| 2016 Q1 | 794.7 Million INR | 15.29% |
| 2016 FY | 2.87 Billion INR | 3.21% |
| 2016 Q3 | 659.3 Million INR | -14.62% |
| 2016 Q2 | 772.2 Million INR | -2.83% |
| 2016 Q4 | 710.2 Million INR | 7.72% |
| 2015 Q2 | 672 Million INR | 1.05% |
| 2015 Q1 | 665 Million INR | -0.75% |
| 2015 FY | 2.78 Billion INR | 15.34% |
| 2015 Q3 | 720.2 Million INR | 7.17% |
| 2015 Q4 | 689.3 Million INR | -4.29% |
| 2014 Q4 | 670 Million INR | 14.86% |
| 2014 FY | 2.41 Billion INR | 2.67% |
| 2014 Q1 | 595.8 Million INR | 12.97% |
| 2014 Q2 | 576 Million INR | -3.32% |
| 2014 Q3 | 583.3 Million INR | 1.27% |
| 2013 Q2 | 616.1 Million INR | -4.0% |
| 2013 FY | 2.35 Billion INR | 6.28% |
| 2013 Q4 | 527.4 Million INR | -7.15% |
| 2013 Q3 | 568 Million INR | -7.81% |
| 2013 Q1 | 641.8 Million INR | 3.9% |
| 2012 FY | 2.21 Billion INR | 14.95% |
| 2012 Q2 | 570.6 Million INR | 2.28% |
| 2012 Q1 | 557.9 Million INR | 0.0% |
| 2012 Q4 | 617.7 Million INR | 26.4% |
| 2012 Q3 | 488.7 Million INR | -14.35% |
| 2011 FY | 1.92 Billion INR | 3.21% |
| 2010 FY | 1.86 Billion INR | 16.88% |
| 2009 FY | 1.59 Billion INR | 13.79% |
| 2008 FY | 1.4 Billion INR | 9.98% |
| 2007 FY | 1.27 Billion INR | 6.18% |
| 2006 FY | 1.2 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 98.8% |
| NATCO Pharma Limited | 40.02 Billion INR | 85.456% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 44.638% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -124.518% |
| Achyut Healthcare Limited | 61.36 Million INR | -9384.43% |
| Ajanta Pharma Limited | 42.08 Billion INR | 86.17% |
| Alkem Laboratories Limited | 126.67 Billion INR | 95.405% |
| Alpa Laboratories Limited | 1.08 Billion INR | -435.273% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 90.477% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 55.072% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 97.972% |
| Bajaj HealthCare Limited | 4.73 Billion INR | -22.946% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 24.433% |
| Brooks Laboratories Limited | 794.86 Million INR | -632.266% |
| Divi's Laboratories Limited | 78.45 Billion INR | 92.581% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 97.915% |
| Eris Lifesciences Limited | 20.09 Billion INR | 71.03% |
| FDC Limited | 19.42 Billion INR | 70.043% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 95.073% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 74.507% |
| Granules India Limited | 45.06 Billion INR | 87.084% |
| Gufic Biosciences Limited | 8.06 Billion INR | 27.845% |
| Hester Biosciences Limited | 3.04 Billion INR | -91.121% |
| Indoco Remedies Limited | 17.89 Billion INR | 67.473% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 54.559% |
| Ipca Laboratories Limited | 76.22 Billion INR | 92.364% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -178.89% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -1054.369% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -457.866% |
| Laurus Labs Limited | 50.01 Billion INR | 88.363% |
| Lupin Limited | 200.1 Billion INR | 97.091% |
| Mankind Pharma Limited | 103.34 Billion INR | 94.368% |
| Medicamen Biotech Limited | 1.79 Billion INR | -224.612% |
| Medico Remedies Limited | 1.44 Billion INR | -301.633% |
| Megasoft Limited | 373.95 Million INR | -1456.479% |
| Piramal Pharma Limited | 81.71 Billion INR | 92.877% |
| Sigachi Industries Limited | 3.98 Billion INR | -45.893% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -670.465% |
| Unichem Laboratories Limited | 16.57 Billion INR | 64.882% |
| Wanbury Limited | 5.75 Billion INR | -1.112% |
| Windlas Biotech Limited | 6.3 Billion INR | 7.751% |
| ZIM Laboratories Limited | 3.67 Billion INR | -58.414% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 96.94% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 49.442% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -38.179% |
| Bal Pharma Limited | 3.39 Billion INR | -71.585% |
| Strides Pharma Science Limited | 40.51 Billion INR | 85.632% |
| Venus Remedies Limited | 5.91 Billion INR | 1.589% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 67.94% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 65.438% |
| Shilpa Medicare Limited | 11.51 Billion INR | 49.457% |
| Aarti Drugs Limited | 25.28 Billion INR | 76.981% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 72.531% |
| Suven Life Sciences Limited | 116.92 Million INR | -4877.807% |
| Ind-Swift Limited | 5.02 Billion INR | -15.838% |
| Valiant Laboratories Limited | 1.82 Billion INR | -219.707% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 83.295% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 52.999% |
| Themis Medicare Limited | 3.81 Billion INR | -52.465% |
| Hikal Limited | 17.84 Billion INR | 67.385% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 94.512% |
| Sequent Scientific Limited | 13.69 Billion INR | 57.506% |
| Novartis India Limited | 3.35 Billion INR | -73.71% |
| Wockhardt Limited | 27.89 Billion INR | 79.131% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 91.316% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -1353.842% |
| Neuland Laboratories Limited | 15.58 Billion INR | 62.655% |
| Morepen Laboratories Limited | 17.01 Billion INR | 65.8% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -277.043% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -57.911% |